1. Chobanian AV, Bakris GL, Black HR et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood pressure. JAMA 2003; 289: 2560–72.
2. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: The task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–87.
3. Профилактика, диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр). Кардиоваск. тер. и проф. 2004; Прил.
4. Mancia G, Laurent St, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–58.
5. Jamerson K, Weber MA, Bakris GL et al. for ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorthiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417–26.
6. PROGRESS Collaborative Study Group. Randomized trial of perindopril based blood pressure-lowering regimen among 6108 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41.
7. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829–40.
8. Beckett NS, Peters R, Fletcher AE et al. for HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887–98.
9. Trenkwalder P, Schaetzl R, Borbas E et al. Efficacy and safety of the combination of amlodipine 10/valsartan 160 in hypertensive patients not controlled by the combination of ramipril 5/felodipine 5 – the EXPRESS-C trial. J Hypertens 2007; 25 (Suppl. 2): S228 (abstr. P24.261).
10. Philipp T, Smith TR, Glazer R et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther 2007; 29: 563–80.
11. Poldermans D, Glazer R, Karagianniss S et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007; 29: 279–89.
12. Allemann Y, Fraile B, Lambert M et al. Efficacy of the Combination of Amlodipine and Valsartan in Patients With Hypertension Uncontrolled With Previous Monotherapy: The Exforge in Failure After Single Therapy (EX-FAST) Study. J Clin Hypertens 2008; 10: 1–10.
13. Calvo C, Hermida RC, Ayala DE, Ruilope LM. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension. J Hypertens 2004; 22: 837–46.
14. Fogari R, Zoppi A, Mugellini A et al. Comparative efficacy of losartan and valsartan in mild-to-moderate hypertension: Results of 24-hour ambulatory blood pressure monitoring. Cur Ther Res 1999; 60: 195–206.
15. Fogari R, Mugellini A, Zoppi A et al. A double-blind, crossover study of the antihypertensive efficacy of angiotensin II-receptor antagonists and their activation of the renin-angiotensin system. Cur Ther Res 2000; 61: 669–79.
16. Fogari R, Mugellini A, Zoppi A et al. Efficacy of losartan, valsartan, and telmisartan in patients with mild to moderate hypertension: A double-blind, placebo-controlled, crossover study using ambulatory blood pressure monitoring. Cur Ther Res 2002; 63: 1–14.
17. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE Randomised trial. Lancet 2004; 363: 2022–31.
18. Pfeffer MA, McMurray JJ, Velazquez EJ et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906.
19. Cohn JN, Tognoni G. A Randomised trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001; 345: 1667–75.
20. Mochizuki S, Dahlof B, Shimizu M et al. for the Jikei Heart Study Group. Valsartan in a Japanese population with hypertension and other cardiovascular disease (Jikei Heart Study): a randomised, open-label, blinded endpoint morbidity-mortality study. Lancet 2007; 369: 1431–9.
21. Sawada T, Yamada H, Dahlof B et al. for the KYOTO HEART Study Group. Effacts of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high cardiovascular risks: KYOTO HEART Study. Eur Heart J 2009; doi 10.1093/eurheartj/ehp363.
22. Ogihara T, Nakao K, Fukui T et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393–8.
23. Kasanuki H, Hagiwara N, Hosoda S et al. For the HIJ-CREATE investigators. Angiotensin II receptor blocker-based vs. non-angiotensin II receptor blocker-based therapy in patients with angiographically documented coronary artery disease and hypertension: the Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease (HIJ-CREATE). Eur Heart J 2009; 30: 1203–12.
24. Dahlof B, Devereux RB, Kjeldsen SE et al. for LIFE Study Group. LIFE Study Group Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995–1003.
25. Schrader J, Luders S, Kulschewski A et al. Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003; 34: 1699–703.
26. Schrader J, Luders S, Kulschewski A et al. for the MOSES Study Group. Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention: Principal Results of a Prospective Randomized Controlled Study (MOSES). Stroke 2005; 36: 1218–24.
27. Yusuf S, Diener H-Ch, Sacco RL et al. for the PRoFESS study Group. Telmisartan to prevent Recurrent Stroke and Cardiovascular events. N Engl J Med 2008; 359: 1225–37.
28. The ONTARGET Investigators. Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular events. N Engl J Med 2008; 358: 1547–1559.
29. The TRANSCEND Investigators. Effects of the angiotensin-receptor blocker telmisartan on cardiovascular events in high-risk intolerant to angiotensin-converting enzyme inhibitors: a randomized controlled trial. Lancet 2008doi: 10.1016/S0140–6736 (08)61242–8.

Ю.М.Лопатин

Волгоградский государственный медицинский университет, Волгоградский областной кардиологический центр